Abstract
The development of SARS-CoV-2 mRNA vaccines is closely linked to advancements in mRNA manufacturing technology. Structural modifications, such as replacing uridine with 1-methylpseudouridine (1mψ), enhance translation efficiency and help the mRNA evade immune detection. Lipid nanoparticles (LNPs) serve as an effective delivery system. Vaccines like BNT162b2 and mRNA-1273 target the receptor-binding domain (RBD) of the spike (S) protein, prompting B cells to produce neutralizing antibodies that block the RBD from binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor, preventing infection. These vaccines also stimulate adaptive immune responses by activating CD4+ and CD8+ T cells, with mRNA functioning as an endogenous antigen. Antigen-presenting cells (APCs) present the vaccine antigens via major histocompatibility complex (MHC) class I and II pathways, with CD8+ T cells recognizing MHC class I and destroying infected cells, while CD4+ T cells recognize MHC class II and assist in B cell maturation and antibody production. While mRNA vaccines have proven effective in neutralizing SARS-CoV-2, challenges remain, including the decline in neutralizing antibody titers over time and the emergence of new viral variants.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
